Sign In
Buy PRCT
$16.69
-0.86 (-4.90%)
At Close: Jul 24, 2026
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
04:05pm, Thursday, 09'th Apr 2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing t
Reviewing PROCEPT BioRobotics (NASDAQ:PRCT) & OPKO Health (NASDAQ:OPK)
01:40am, Monday, 06'th Apr 2026
OPKO Health (NASDAQ: OPK - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two
PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC
05:32am, Saturday, 04'th Apr 2026
SG Americas Securities LLC boosted its stake in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by 142.0% in the undefined quarter, according to the company in its most recent 13F filing with the Secur
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
09:00am, Wednesday, 01'st Apr 2026
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost
Procept BioRobotics: An Undervalued Surgical Robotics Growth Story
07:29am, Monday, 30'th Mar 2026
PROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market. PRCT trades at 2.9x forward EV/2026E revenue, a deep discount
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
10:00am, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors a
PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES
09:00am, Thursday, 26'th Mar 2026
Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales Procept BioRobotics set aggressive revenue targets while a internal pricing c
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
09:00am, Wednesday, 25'th Mar 2026
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, March 25, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) los
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
05:11pm, Tuesday, 24'th Mar 2026
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
07:00am, Monday, 23'rd Mar 2026
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia Updated European Associati
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
10:00am, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors ar
PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES
09:30am, Wednesday, 18'th Mar 2026
Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales NEW YORK, March 18, 2026 /PRNewswire/ -- Procept BioRobotics (NASDAQ: PRCT) g
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
06:05pm, Tuesday, 17'th Mar 2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such i
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation (NASDAQ: PRCT) ("PROCEPT BioRo
